Dosage and usage of sevabertinib-Hyrnuo

Sevabertinib -Hyrnuo is used to treat patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) . Its dosage and usage need to be adjusted according to the specific conditions of the patient. First, patient selection should be based on the presence of HER2 (ERBB2) TKD activating mutations in tumor specimens. Only patients who meet this criterion are suitable for treatment with Hyrnuo.

According to the recommended protocol,the starting dose of sevabertinib is 20 mg twice daily, which needs to be taken orally with food, which can improve the absorption and tolerance of the drug. Patients should swallow the tablet whole when taking it and avoid cutting, crushing or chewing the tablet to ensure the effectiveness of the medicine. Treatment should be continued until disease progression or unacceptable toxicity occurs.

During medication, patients may experience missed doses or vomiting. If a dose is missed, it is recommended to take the missed dose as soon as possible before the next scheduled dose, but never take two doses at the same time to make up for the missed dose. If vomiting occurs during administration, no additional dose is required and administration will resume at the next scheduled time.

In addition, dose adjustments may be necessary in response to the occurrence of adverse reactions. The initial dose can be reduced to 10 mg twice daily based on patient tolerance; if tolerance issues arise again, the dose can be further reduced to 10 mg once daily. If the patient still cannot tolerate the once-daily 10 mg dose, permanent discontinuation of sevabertinib should be considered to ensure patient safety and therapeutic efficacy.

In shortThe dosage and usage of sevabertinib need to be adjusted according to the patient's individual condition. Medical staff should closely monitor the patient's medication to ensure that the risk of adverse reactions is minimized during the treatment process while improving the efficacy of the drug. If patients experience any discomfort during medication, they need to communicate with medical staff in a timely manner so that reasonable treatment and adjustments can be made.

Reference materials:https://en.wikipedia.org/wiki/Sevabertinib